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ABSTRACT 
Objective: The present study was performed in order to evaluate potential genotoxicity and the histopathological alteration of a traditional herbal 
prescription Heptex that used in the treatment of liver disease.  
Methods: The genotoxicity were evaluated using the in vivo chromosome aberration and micronucleus assays in bone marrow cells of male and 
female Sprague-Dawley rats. In addition, in vitro chromosome aberration assay in Chinese hamster ovary (CHO) cells and bacterial reverse 
mutations assay in Salmonella typhimurium strains and Escherichia coli (WP2-uvrA/) with and without metabolic activation system (S9 mix) were 
performed. Histopathological study was conducted in liver, ovary and testis tissue of Sprague-Dawley rats.  
Results: The genotoxicity assessment showed that Heptex did not significantly increase the number of chromosomal aberrations and frequencies of 
micro nucleated polychromatic erythrocytes in bone marrow cells of both male and female rats. In addition, there were no increases in the number 
of revertant colonies at any concentrations of Heptex used in the study. Heptex did not produce any structural aberration in CHO cells in the 
presence or absence of S9 mix. In addition, there were no histopathological changes induced by Heptex in rat liver, ovary and testis.  
Conclusion: Based on abovementioned findings, we can conclude that Heptex is generally non-toxic and does not exhibit genotoxicity or 
histopathological alteration. 
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INTRODUCTION 
Heptex® capsule consists of Dukong Anak powdered extract from 
aerial parts of Phyllanthus niruri and Milk thistle powdered extract 
from fruits of Silybum marianum (L.) and function as liver tonic and 
Hepatitis.forbeneficial Phyllanthus niruri genus(Heptex,
popularmostone of theisPhyllanthaceae)Phyllanthus, family
tropical and subtropical herbal plants [1]. Phyllanthus niruri is a 
well-known plant in Malaysian traditional medicine, locally known 
as Dukung anak that means carry baby; because the plants carry the 
fruits on their backs and underneath the feathered-like leaves [2, 3] 
The phytochemical compounds of many of Phyllanthus species such as 
tannins, ellagitannins flavonoids have been isolated and characterized 
[2, 4, 5]. Several studies have shown antioxidants activity of various 
Phyllanthus species using different solvents and methods of 
extractions [4, 6, 7]. The potential pharmacological effects of the many 
of these isolated compounds have been assessing [8, 9]. 
The plants of genus Phyllanthus have long been used to treat liver 
diseases [10]. In fact, a wide number of experimental studies have 
demonstrated the hepato protective potential of Phyllanthus plants 
in vitro and in vivo systems [11-14]. Phyllanthus niruri have been 
report to have hepato protective activity [7, 15], antioxidant [16] 
and lipid lowering activity [17]. Its actions were evaluated on 
various organs including liver, kidneys and testes [18].  
Silymarin, an extract from the milk thistle fruit (Silybum marianum, 
Family Asteraceae) has been utilized for remedy of liver diseases 
such as sirrhosis or hepatitis for many years [19-21]. Silymarin is a 
mixture of flavonoids and polyphenols and it is contained several 
different flavonoids, like silibinin, isosilibinin, silichristin and 
silidianin. Silibinin is the major bioactive component of this material 
[22]. Silymarin has membrane-stabilizing and antioxidant activity, it 
promotes hepatocyte regeneration, reduces an inflammatory 
reaction, and inhibits fibrogenesis [23]. The pharmacological data 
show that Silymarin possesses fairly specific effects on cell-
regulating mechanisms, beyond the well known reactive oxygen 
species (ROS) scavenging properties confirmed in new studies 
indicating a potential to reduce toxic effects of other drugs [24]. 
Herbal medicines are very popular in developing and 
underdeveloped countries. Reports indicate that the ideal herbal 
drugs are very safe and free from side effect is false [25]. Therefore, 
clear understanding of potential adverse effect of herbs used by the 
human population is necessary for implementing safety measures to 
the public. There is paucity of evidence from literature on possible 
genotoxicity of Phyllanthus niruri extract.  
Therefore, the aim of this study was to determine the genotoxicity 
and histopathological changes of Heptex in Sprague-Dawley rats. 
The in vivo genotoxicity study was conducted by using chromosome 
aberration assay and micronucleus test. The in vitro genotoxicity 
study was conduct using the chromosome aberration assay in 
Chinese hamster ovary cells and the bacterial reverse mutation 
assay. In addition, histopathological study was conducted on the 
liver, ovary and testis of Sprague-Dawley rats. 
MATERIALS AND METHODS  
Drug 
Heptex® hard gelatin vegetable origin capsule consist of 200 mg 
Dukong Anak powdered extract from aerial parts of Phyllanthus 
niruri and 100 mg Milk thistle powdered Extract from fruits of 
Silybum marianum (L.) as active ingredients. 100 mg of starch 1500 
(inactive ingredient) was used as diluents. The extracts were 
obtained from TPM Biotech Sdn Bhd, Kuala Lumpur, Malaysia. 
Animals 
Fifty Sprague-Dawley male and female rats (25♀, 25♂) with a body 
weight ranging from 120 to 150 g for both sexes were obtained from 
Misr University for Science and Technology, 6th of October, Egypt. 
The animals were acclimated for a period of one week before the 
beginning of the experiments. Rats were maintained under 
controlled of temperature (22±3 °C), 50-55% relative humidity and 
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light cycle of 12 h light: 12 h dark and were fed standard granulated 
diet and water ad labium. This study was conducted at the Faculty of 
Pharmacy Animal Facility–Ain shams University in compliance with 
the OECD good laboratory practice principles and applicable 
standard operating procedures. 
In vivo treatment and sampling 
Rats of both sexes were randomly divided into five groups of five 
rats per group. Negative control group: animals administered orally 
distilled water at the dose (10 ml/kg b.w.). Positive control group: 
animals were injected intraperitoneally (IP) with a single dose of 50 
mg/kg Cyclophosphamide. Heptex groups: three groups of rats were 
administered orally heptex at three dose levels (250, 500 and 1000 
mg/kg) for consecutive 14 days.  
In vivo chromosomal aberration analysis 
At the end of treatment, schedule the animals of each experimental 
group were injected IP with 5 ml/kg B. W of 0.5% colchicine as a 
metaphase arresting substance. Two h after injection animals were 
sacrificed by dislocation of nick vertebra for preparation of bone 
marrow cells chromosomes according to [26]. Bone marrow cells 
were collected from both femurs by flushing in saline solution and 
then incubated in hypotonic solution (kcl 0.56%) at 37 °C for 30 min, 
fixed in carnoy”s fixative. The cells were re suspended in small 
volume of fixative; dropped onto clean chilled slid, flam dried and 
stained with 10% buffered Giemsa (pH 6.8). One hundred good 
metaphase spreads from bone marrow of each animal were 
examined microscopically to detect the different types of 
chromosomal abnormalities. 
Mitotic index determination 
The mitotic index was used to determine the rate of cell division. 
The slides prepared for the assessment of chromosomal aberrations 
were also use for calculating the mitotic index. Randomly selected 
views on the slides were monitored to determine the number of 
dividing cells (metaphase stage) and the total number of cells. At 
least 1000 cells were examined in each preparation. The mitotic 
index calculated as the ratio of the number of dividing cells to the 
total number of cells, multiplied by 100.  
In vivo mammalian micronucleus test 
A micronucleus (MN) formed during the metaphase/anaphase 
transition of mitotic cell division. It may arise from a whole lagging 
chromosome or an acentric chromosome fragment detaching from a 
chromosome after breakage which do not integrate in the daughter 
nuclei. The micronucleus assay was performed in accordance with 
the organization for economic cooperation and development (OECD) 
guideline 474 [28]. The bone marrow was extracted, smear 
preparations made by using fetal calf serum and stained in 5% 
phosphate buffered Giemsa (pH 6.8) for 5mi. Polychromatic 
erythrocytes scored for micronuclei under the microscope, at least 
2000 immature erythrocytes per animal scored for the incidence of 
micro-nucleated immature erythrocytes. 
Bacterial strains, chinese hamster ovary (CHO) cells and S9 
Salmonella typhimurium strains TA98 and TA97a, TA100, and 
TA1535, and Escherichia coli strain WP2uvrA were purchased from 
Moltex (Molecular Toxicology Inc., Boone, NC, USA). Chinese 
hamster ovary (CHO) cells were obtained from VACSERA (Holding 
Company for Biological Products & Vaccines, Agouza, Egypt). 
Lyophilized rat liver fraction (S9) induced by Aroclor 1254, was 
purchased from Moltex (Molecular Toxicology Inc., Boon, NC, USA).  
Positive control mutagens 
Sodium azide (NaN3, Sigma), 9-aminoacridine, (9AA, Aldrich 
Chemical Company Limited), 2-nitrofluorene (NF, Aldrich Chemical 
Company Limited), benzo[a] Pyrene (BP, Aldrich Chemical Company 
Limited),2-aminoanthracene (2-AAN, Aldrich Chemical Company 
Limited), Methyl methanesulfonate (MMS, Aldrich Chemical 
Company Limited). 
The S9 cofactor mix presents in the bacterial mutation assay 
consisted of 10% (v/v) S9 tissue fraction, 33 mmol potassium 
chloride (KCl), 8 mmol magnesium chloride (MgCl2), 4 mmol 
nicotinamide adenine dinucleotide phosphate (NADP), 4 mmol 
nicotinamide adenine dinucleotide (NAD), and 5 mM glucose-6-
phosphate (G-6-P) prepared in 100 mmol phosphate buffer (PBS, pH 
7.4). For mammalian chromosomal aberration test, the S9 mix 
consisted of 30% (v/v) S9 tissue fraction, 5 mmol MgCl, 33 mmol 
KCl, 5 mmol G-6-P, 4 mmol NADP, and 4 mmol HEPES buffer 
prepared in the complete medium. As in the bacterial reverse 
mutation assay, the 2-NF and 9-AA were dissolved in sterile distilled 
water, whereas NaN3, MMS and BP were dissolved in dimethyl 
sulfoxide (DMSO).  
In vitro chromosomal aberration assay  
The test was conducted in accordance with OECD Guidelines for the 
testing of chemicals no. 473 (OECD, 1997), using Chinese hamster 
ovary CHO-K1 (ATCC/CCL-61) cells. The cells were thawed in 
culture medium and grown for more than 7 days as a monolayer. 
Cells were cultured in reconstituted minimum essential media 
(MEM) (Gibco-Invitrogen, USA) supplemented with 2.2 g of sodium 
bicarbonate, 292 mg of L-glutamine, streptomycin sulfate (100 
µg/ml), penicillin G · Na (105 units), and 10% (v/v) fetal bovine 
serum (FBS; Gibco-Invitrogen, USA) per liter. The cultures were 
incubated at 37 °C in a humidified atmosphere with 1.5% CO2. Six 
different concentrations at the nontoxic range were used (100, 50, 
10, 5, 2.5 and 1 µg/ml). Mitomycin C was used as a positive control 
substance without metabolic activation and cyclophosphamide 
(CPA) with metabolic activation. For chromosome preparation 
0.16 μg/ml Colcemid solution (Gibco,USA) was added into the 
culture and incubated for 3 hours. Cells were harvested by 
trypsinization and centrifugation, swollen by freshly prepared 
0.56% KCl, and fixed with ice-cold freshly prepared mixture of 3: 1 
methanol:  glacial acetic acid. The smear was allowed to be air-dried 
and stained with buffered Geimsa before microscopic observation. 
The frequency of cells with chromosome structural aberrations or 
numerical disorders was scored in 100 well-spread metaphases for 
each dose in duplicate.  
Bacterial reverse mutation assay (Ames test) 
The mutagenicity test was performed by the standard plate 
incorporation procedure with and without the metabolic activation 
system (S9mixture) according to the guidelines of OECD 471(1997) 
for testing of chemicals in a Bacterial Reverse Mutation Test. Briefly, 
100 µl of bacterial suspension an (containing approximately 1–
2×109
Histopathological analysis 
 cells/ml) of each strain was added into culture tubes. The 
culture tube contained overlay agar, 100 µl of Heptex aqueous 
extract (100, 50, 10, 5, 2.5 and 1µg/plate) or 50 µl standard 
mutagens (positive control) or de ionised water (negative control), 
and 500 µl of sodium phosphate buffer (without S9) or 500 µl of S9 
mixture. After 72 h of incubation at 37 °C, all plates were checked for 
the presence of the background lawn and compared to the negative 
control group plates. Numbers of revertant bacterial colonies were 
counted and compared with those in negative and positive control 
plates. Every experiment was carried out in triplicate. 2-
nitrofluorene (2-NF), 9-aminoacridine (9-AA), sodium azide and 4-
nitroquinoline X-oxide (4NQO)] were employed as positive 
control.  
The liver, ovary and testis tissues of male and female control and 
heptex treated rats were fixed in 10% buffered formalin and 
processed to hematoxylin and eosin (H&E) stained sections. Briefly, 
tissues were dehydrated in ascending grades of alcohol, cleared in 
xylene and embedded in paraffin wax. Paraffin sections (5 μm 
thicknesses) of all organs were stained with hematoxylin and eosin 
and histopathologically examined by light microscopy. 
Statistical analysis 
All data obtained in this study were expressed in mean±standard 
deviation (SD). Comparisons between groups were performed using 
one-way analysis of variance (ANOVA) and Duncan’s multiple range 
tests by SPSS (Statistical Package for Social Sciences) software 
statistical (IBM, NY, and USA). Significance of difference between 
groups was determined by (P ≤0.05).  
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RESULTS 
In vivo chromosomal aberrations 
The effects of Heptex powder at concentrations (250, 500 and 1000 
mg/kg b.w.) on rat bone marrow cells chromosomes of both sexes are 
shown in table 1 and 2. The results showed that Heptex powder 
induced in significant decrease in the frequencies of most individuals 
and total chromosomal aberrations than those of control group. 
Meanwhile, cyclophosphamide caused the significant increase in the 
mean values of individuals and total chromosomal aberrations than 
those of control and heptex treated groups (P≤0.01). 
Mitotic index 
Results showed that there were no significant differences between 
mitotic activities of Heptex three doses in bone marrow cells of both 
sexes as shown in (fig. 1). While, cyclophosphamide as expected 
significantly reduced the activity of mitotic index (P≤0.01). than 
control and Heptex groups. 
  
Table 1: Chromosome aberrations induced in bone marrow cells of Heptex®
Items 
treated male rats 
-ve control +ve control H 250 mg/kg H 500 mg/kg H 1000 mg/kg 
Numerical chromosomal aberrations n- 2.40±1.14 ab 3.60±0.54 a 2.60±0.54 ab 2.20±1.30 b 2.20±0.83 b 
n+ 0 b 1.60±0.55 a 0.40±0.55 b 0.60±0.54 b 0.80±0.83 b 
Polyploidy 1.00±0.02 b 2.40±0.89 a 0.60±0.54 b 0.80±0.83 b 1.00±1.00 b 
Total 3.40±1.14 b 7.60±1.14 a 3.60±0.89 b 3.80±1.92 b 3.40±0.54 b 
Structural chromosomal aberrations Dicentric 0.60±0.54 b 2.00±1.22 a 0.40±0.54 b 0.40±0.54 b 0.60±0.54 b 
CF 0 c 2.00±0.70 a 0.40±0.54 bc 0.60±0.54 bc 0.80±0.44 b 
Ring 0 b 1.80±0.44 a 0.60±0.55 b 0.60±0.89 b 0.60±0.54 b 
Break 2.00±0.70 b 4.40±1.67 a 1.20±0.44 b 1.20±0.44 b 1.00±0.70 b 
Chr gap 0 b 0.60±0.55 a 0 b 0 b 0 b 
Cht gap 2.00±0. 71 b 3.20±0.83 a 1.40±0.89 b 1.75±0.50 b 1.67±0.57 b 
Del 0 b 3.00±1.41 a 0.60±0.54 b 0.60±0.89 b 0.75±0.50 b 
End to end 0 b 2.20±0.84 a 0.60±0.54 b 0.80±0.83 b 0.80±0.44 b 
CA 3.00±0.71 b 6.00±0.71 a 2.20±0.83 bc 1.60±1.34 c 1.80±0.83 bc 
Fragment 1.60±0.53 b 3.40±1.81 a 1.20±0.83 b  1.50±0.57 b 1.25±0.95 b 
 Total  9.20±1.09 b 28.60±1.81 a 8.60±0.89 b 8.40±2.07 b 8.20±0.83 b 
Total chromosomal aberrations excluding gap 10.00±1.22 b 31.00±5.33 a 11.00±1.14 b 10.80±0.83 b 10.00±1.87 b 
Total chromosomal aberrations including gap 12.60±0.54 b 36.20±2.16 a 12.40±1.34 b 12.20±0.44 b 11.60±0.89 b 
Data are presented as mean±SD (n=5). Statistical analysis was carried out by one way ANOVA followed by Duncan’s post hoc Test. Mean values 
followed with different letters within the same column are significantly different from one another (P≤0.01). 
 
Table 2: Chromosome aberrations induced in bone marrow cells of Heptex P®PP Ptreated female rats 
Items -ve Control +ve Control H 250 mg/kg H 500 mg/kg H 1000 mg/kg 
Numerical chromosomal aberrations n- 2.00±0.70 a 2.20±0.84 a 1.40±1.14 a 1.40±1.34 a 1.25±0.50 a 
n+ 0 b 1.50±0.58 a 0.40±0.54 b 0.40±0.54 b 0.40±0.54 b 
Polyploidy 1.00±0.48 b 2.20±0.84 a 0.60±0.83 b 1.00±0.81 b 0.80±0.83 b 
Total 2.60±0.89 b 5.60±0.55 a 2.40±0.89 c 2.60±0.54 b 2.20±0.83 b 
Structural chromosomal aberrations Dicentric 0.80±0.44 b 2.00±0.71 a 0.80±0.44 b 0.60±0.54 b 0.60±0.54 b 
CF 0 c 2.75±0.50 a 0.40±0.54 bc 0.60±0.54 bc 0.75±0.50 b 
Ring 0 b 1.40±0.55 a 0.60±0.54 ab 0.60±0.89 ab 0.60±0.54 ab 
Break 1.80±0.44 b 3.60±0.95 a 0.60±0.55 b 0.60±0.54 b 0.60±0.54 b 
Chr gap 0 b 0.60±0.54 a 0 b 0 b 0 b 
Cht gap 2.00±0.05 b 3.00±0.71 a 1.25±0.95 bc 1.00±0.70 c 1.00±0.70 c 
Del 00 b 2.50±058 a 0.60±0.54 b 1.00±1.00 b 1.00±1.00 b 
End to end 00 c 2.60±0.89 a 0.80±0.44 bc 0.80±0.84 bc 1.00±0.70 b 
CA 2.60±0.54 b 5.20±0.84 a 2.40±0.54 b 1.60±1.14 b 1.60±1.14 b 
Fragment 1.00±0.54 b 2.20±0.83 a 1.00±0.70 b 0.80±0.83 b 0.80±0.83 b 
Total  8.20±0.83 b 24.80±3.11 a 8.20±1.48 b 7.60±1.51 b 7.80±1.30 b 
Total chromosomal aberrations excluding gap 8.80±0.84 b 27.00±2.82 a 9.60±1.34 b 9.20±0.83 b 9.20±2.16 b 
Total chromosomal aberrations including gap 10.80±0.83 b 30.40±3.11 a 10.60±0.89 b 10.20±1.09 b 10.00±1.58 b 
Data are presented as mean±SD (n=5). Statistical analysis was carried out by one way ANOVA followed by Duncan’s post hoc Test. Mean values 
followed with different letters within the same column are significantly different from one another (P≤0.01). 
 
 
Fig. 1: Mitotic index in bone marrow cells of Heptex treated rats 
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In vivo bone marrow micronucleus 
The ability of Heptex to induce chromosome mutations was 
analyzed using the polychromatic erythrocytes micronucleus test in 
male and female rats. The frequencies and percentage of micro 
nucleated polychromatic erythrocytes (MNPCEs) of all experimental 
groups are illustrated in (table 3). Results showed that Heptex 
extract three doses caused the statistically insignificant decrease in 
the frequencies of MNPCEs than the control value. Meanwhile, 
cyclophosphamide significantly increases the frequency of MNPCEs 
(P≤0.01) over control and Heptex extract tested doses. 
In vitro chromosome aberrations 
The results of chromosomal aberrations test were presented in table 
4. There was no statistically significant induction of chromosomal 
aberration observed in heptex treated CHO-K1 cells at any 
concentrations as compared to solvent group. In contrast, the 
incidence of aberrant cells in both positive control groups was 
significantly (P≤0.01) increased as compared with solvent and 
Heptex groups. 
Bacterial reverse mutation 
The results of reverse mutation test are summarized in Table 5. The 
data showed no significant increase in the number of revertant 
colonies as a result of Heptex was observed in the four strains of S. 
typhimurium (TA98, TA100, TA1535 and TA1537) and in E. coli 
(WP2uvrA
 
) at any tested concentration with those of the 
corresponding solvent controls in either the absence or presence of 
S9 mix. However, the number of revertant colonies in positive 
controls increased remarkably (>two folds) with or without S9 mix. 
Table 3: Frequencies of micronucleated polychromatic erythrocytes in Heptex®
 Treatment 
treated rats 
Dose mg/kg body 
weight 
Frequency of micronucleated polychromatic 
erythrocytes  M±SD 
Micronucleated polychromatic 
erythrocytes %  M±SD 
♂ ♀ ♂ ♀ 
Negative 
Control 
0 8.20±1.48 b 8.80±0.83 b 0.41±0.07 b 0.44±0.04 b 
Positive 
Control 
50 35.20±9.20 a 38.20±9.12 a 1.91±0.45 a 1.76±0.46 a 
Heptex 250 8.00+0.70 b 8.40+0.54 b  0.40+0.03 b 0.42+0.02 b 
500 7.60+0.89 b 8.20+0.83 b  0.38+0.04 b 0.41+0.04 b 
1000 7.40+0.54 b 8.00+0.70 b  0.37+0.02 b 0.40+0.03 b 
Two thousand cells per animal were analyzed. Data were expressed as mean±SD (n=5). Mean values followed with different letters within the same 
column are significantly different from one another (P_0.01). 
 
Table 4: Chromosomal aberration induced by Heptex in CHO-K1 cells 














Gaps Chromatid Chromosome 
Br Ex Br Dic Ring 
 Solvent  -   100 0 g 0 c 0 c 0 d 0 b 0 c 0 c 0 g 0.00 g 


















- 1  100 0 g 0 c 0 c 0 d 0 b 0 c 0 c 0.00 g 0 g 
- 2.5  100 0 g 0 c 0 c 0 d 0 b 0 c 0 c 0.00 g 0 g 
- 5  100 1.33+0.5 
7 fg 




- 10  100 3.33+0.5
7 fg 






































 10  100 18.67+1.



















+ 1  100 0 g 0 0 c 0 d 0 b 0 c 0 c 0.00 g 0.00 g 
+ 2.5  100 0 g 0 0 c 0 d 0 b 0 c 0 c 0.00 g 0.00 g 
+ 5  100 1.33+0.5
73 




+ 10  100 2.67+1.1
5 




0 c 5+2.00 fg 5+2.00 fg 




















0 c 21+3.60 c 21+3.60 c 
Where, Aberrant Cells: numerical cells include polyploid and end reduplicated cells; Chromatid breaks (Br) include chromatid and iso-chromatid 
breaks and fragments; chromatid exchange fig. (Ex) include quadriradials, triradials and complex rearangements. Chromosome breaks (Br) include 
breaks and acentric fragments; (Dic), dicentric chromosome. Data were expressed, as mean±SD. Mean values followed with different letters within 
the same column are significantly different from one another (P≤0.01). 
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Concentration of test material 
(µg/plate) 
Average of revertant colonies (Mean+SD) 
Base Pair Substitution Frame Shift mutation 
TA 100 TA 1535 WP2 uvrA TA 98 TA 97a 
Historical negative (background)  16.00+1.00 b  7.00+1.00 b 12.00+1.00 31.66+1.53 b 26.00+1.00 b 
heptex 1.0 -S9 0 0 d 0 0 0 
+S9 0 c 0 0 0 c 0 
2.5 -S9 0 c 0 0 0 c 0 c 
+S9 0 c 0 0 0 0 
5.0 -S9  0 c 0 0 0 0 
+S9 0 c 0 0 0 0 
10 -S9 0.25+0.015 c  1.03+0.060 c 0 0.13+0.02 c 1.79+0.015 
+S9=S9 0.35+0.014 B  1.126+0.064 c 0 0.23+0.02 c 1.98+0.026 
50 -S9 0 0 0 0 0 
+S9 0 0 0 0 0 
100 -S9 0 0 0 0 0 
+S9 0 0 0 0 0 
Positive control NaN3 NaN3 ENU 2NF 9AA 
88.00+1.00 a  24.66+4.37 a 93.02+6.12 a 71.67+1.53 a 83.00+1.73 a 
 Mean values followed with different letters within the same column are significantly different from one another (P≤0.01). 
 
Histopathological result 
The liver histopathological examination of control and Heptex three 
doses treated rats showed normal structure of hepatic lobules in 
which the hepatocytes arranged in cords radiating from the central 
veins (fig. 2). The sections of ovaries from control rats showed 
normal histological features, illustrating follicles at various stages of 
development, mature ovarian follicle, primary follicle and 
primordial follicle, in addition to post ovulatory corpora lutea (fig. 
3). The ovarian sections from heptex treated rats did not showed 
alteration in the structure of the ovaries. Data obtained in the 
histopathological testicular analysis of rats from the control and 
Heptex treated groups did not reveal any change or inhibition of 
spermatogenetic activity, tubular degeneration and necrosis, 
obstruction in tubule lumens or lymphocytic infiltration (fig. 4). 
 
 
Fig. 2: Section of liver of (A) control and (B) Heptex treated rat showing average central vein (CV) and hepatocytes arranged in cords (H&E x200) 
 
 
Fig. 3: Section of ovary of (A) control and (B) Heptex treated rats showing mature ovarian follicle (mf), primary follicle (p f), primordial 
follicle (arrow) (H&E x150) 
 
 
Fig. 4: Section of testis of (A) control and (B) Heptex treated rat showing average-sized seminiferous tubules showing full 
spermatogenesis (ST) widely separated by average interstitial area (IA) 
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DISCUSSION 
Currently a large and ever expanding global population base prefers 
the use of natural products in treating and preventing medical 
problems. It was believed that natural herbs found among the world 
flora are able to cure various ailments and diseases. Natural herbs 
have presented to human as vast therapeutic value for the variety of 
medicinal plants [27]. Dukung anak (Phyllanthus niruri) is a 
medicinal plant widely used in different regions in the world for the 
treatment of various diseases. Interest of this plant was enhanced 
due to its potential as a remedy for hepatitis B viral infection. 
Although there has been some reports on the health benefits of 
Phyllanthus niruri. The lack of adequate scientific evidence on the 
safety of P. niruri is often a major issue to the acceptance and use of 
this medicinal plant [28]. Generally, plants would produce 
hazardous secondary metabolites that might be used as their 
defensive mechanisms. Following that, several reports have 
indicated the toxicity of some plants used in traditional medicines if 
consumed above certain concentrations, though their potentials to 
cure diseases were also mentioned (29-31). Therefore, despite the 
study about the efficacy and mechanisms of plants to cure diseases, 
it is also vital to study the potential dangers they might present. In 
recent years, genotoxicity have become more important in the 
process of early screening for potential compound (OECD 474 & 475, 
1997). Ames test is a rapid, convenient and widely accepted test for 
identifying substances which can produce genetic damage that leads 
to gene mutation [32] In the present study, results indicated that 
Heptex (Phyllanthus niruri and Milk thistle) not induced significant 
increase in the induction of chromosome aberration in both in vivo 
and in vitro assay and MNPCEs frequencies in bone marrow cells of 
both sexes of Sprague-Dawley rats. In addition, there were no 
increases in the number of revertant colonies at any concentration 
of Heptex with and without metabolic system in S. typhimurium (TA 
98, TA97, TA100 and TA1535) and E. coli (WP2 uvrA). According to 
the data obtained in the present investigation, Heptex is 
nongenotoxic. Moreover, there were no significant differences 
between results of treated groups in the absence and presence of the 
metabolic activation for both tests, The result of the present study 
was in accordance with Asare et al. [28] who confirmed that the 
aqueous leaf extracts of P. niruri did not suggest any toxicity. 
Furthermore, there were no statistical differences between the low 
dose (2000 mg/kg b. wt.) and the high dose (5000 mg/kg b. wt.) 
extract administration. Thus, P. niruri can be considered non-toxic at 
the acute level and consequently, the LD50 of it is more than 5000 
mg/kg b. wt. Asare et al. [33] who observed that Phyllanthus niruri 
extract was not able to promote micronuclei at polychromatic 
erythrocytes bone marrow cells of adult rats treated with a single 
dose of 30 or 300 mg/kg. They concluded that the Phyllanthus niruri 
whole plant extract is non-toxic and the acute oral administration of 
this extract in rats at 300 mg/kg bw does not exhibited genotoxicity. 
De Queiroz et al. [34] observed that the dry extract of Phyllanthus 
niruri did not provoke changes in body weight, weight gain, ration 
and water intake or changes in the frequency of MNPCE or 
cytotoxicity in bone marrow. They proposed that the P. niruri 
extract showed no genotoxic or cytotoxic activities. Tona et al. [35] 
demonstrated that aqueous and ethanol extract of P. niruri orally 
administered to mice at a dose of 500 mg/kg of body weight, once a 
week, for 4 weeks, caused no toxic effects or deaths. In the present 
study, the histopathological analysis of the effect of P. niruri in 
tissues of liver, ovary and testis of rats confirmed the genetic results. 
Histopathological examination revealed that P. niruri did not induce 
any change in the tissues of all used organs. Makoshi et al. [36] 
showed that the rabbit liver samples from the Phyllanthus niruri 
group showed normal liver architecture with no cellular damage. A 
study recently developed by Asare et al. [33] observed that an 
ethanolic extract obtained from P. niruri whole plant was not toxic 
to adult rats treated during 90 days with 30 and 300 mg/kg. 
Hematological, biochemical or histopathological alterations were 
not observed in rats treated with the higher dose. However, the 
lower dose promoted lymphocyte reduction and drastic reduction 
was observed in most liver function test parameters (bilirubin, AST 
and ALT), suggesting some degree of hepatoprotection. Previous 
study reported that Phyllunthus niruri possesses potent antioxidant 
activity that may be responsible for it is antitumor, anticarcinogenic 
and remedy for hepatitis B viral infection mechanism [7, 37]. The 
antioxidant potential of Phyllunthus niruri may be interpret the 
decrease in the frequencies of chromosomal aberrations and the 
micronuclei induced by Heptex. Where, antioxidants act as free 
radical scavengers and they trap the free radicals and give up own 
electrons. Thus, they protect against free radical oxidation molecules 
such as protein, lipid, enzyme, chromosome and DNA [38]. Whereas, 
the previous literature that mentioned above confirmed the safety of 
the Phyllunthus niruri, in addition, there are several studies were 
conducted to evaluate the safety of Milk thistle (Silybum marianum). 
Dixit et al. [39] they mentioned that the silymarin LD50 values were 
385 mg/kg rats and depending on the infusion rate, these values 
vary. With slow infusion (over 2-3 h), the LD50 was 2 g/kg and after, 
oral administration it was 10 g/kg. These data demonstrate that the 
toxicity of silymarin is very low. The extracts of the flowers and 
leaves of Silybum marianum have been used for centuries to treat 
liver disorders. The major activity of Silybum marianum L. is its 
antioxidant property, which makes it useful in the prevention of 
organ-specific toxicities related to the induction of oxidative stress 
[40, 41]. El-Kamary et al. [42] suggested that the standard 
recommended doses of silymarin (300-900 mg/day) are safe. Shaker 
et al. [43] confirmed that one of the important issues about the 
Silybum marianum. is that it may be accepted as a safe herbal 
product with no health hazard or significant side effect.  
CONCLUSION 
The findings of our study indicated that the Heptex extract is 
generally non-toxic and that the oral administration of Heptex 
extracts in rats at 1000 mg/kg BW does not exhibit genotoxicity or 
any histopathological alteration. 
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